Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 2,400 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director Elaine Heron bought 2,400 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were bought at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the director directly owned 47,812 shares in the company, valued at approximately $5,976,500. This represents a 5.28% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Palvella Therapeutics Stock Up 4.8%

Shares of PVLA opened at $141.46 on Monday. The company has a market capitalization of $1.67 billion, a PE ratio of -53.79 and a beta of -0.31. Palvella Therapeutics, Inc. has a 52-week low of $18.23 and a 52-week high of $151.18. The company has a 50-day simple moving average of $94.53 and a 200-day simple moving average of $80.50.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in shares of Palvella Therapeutics by 11.6% during the fourth quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock valued at $5,681,000 after purchasing an additional 5,663 shares during the period. XTX Topco Ltd purchased a new position in shares of Palvella Therapeutics in the fourth quarter valued at $429,000. Virtus Investment Advisers LLC acquired a new stake in Palvella Therapeutics during the 4th quarter valued at $282,000. Superstring Capital Management LP purchased a new stake in Palvella Therapeutics during the 4th quarter worth $2,666,000. Finally, Suvretta Capital Management LLC increased its stake in Palvella Therapeutics by 8.5% during the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock worth $93,408,000 after buying an additional 70,000 shares during the period. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Analysts Set New Price Targets

PVLA has been the topic of several research reports. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. Oppenheimer reissued an “outperform” rating and issued a $200.00 price objective on shares of Palvella Therapeutics in a research note on Monday, December 15th. Chardan Capital lifted their target price on shares of Palvella Therapeutics from $174.00 to $210.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Canaccord Genuity Group upped their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Cantor Fitzgerald raised their price objective on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $176.44.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.